The Effect of Atorvastatin on Inslin Resistance in Patients with Type Two Diabetes

Regarding the controversy about the effects of atorvastatin on blood glucose control and diabetes, we evaluated the effects of atorvastatin on blood glucose and insulin resistance in the present study. 88 type two diabetic patients (T2DP), were treated with anti-diabetes oral agents were enrolled in a double blind randomized clinical trial, placebo control. Then they were randomly classified into two 44 cases groups.  The intervention group took atorvastatin 40 mg daily and control group took placebo for three months and fasting blood glucose (FBS), insulin resistance, HbA1c and lipid profile were measured and compared at the beginning and the end of the study. Data were analyzed using student t-test and paired t-test. This study with research ethics code IR.ARAKMU.REC.90.108.10 has been approved by research ethics committee at Arak University of Medical Sciences. After three months, insulin, insulin resistance and HbA1c decreased significantly in the intervention group than control group, while FBS non-significantly decreased. Total cholesterol and LDL cholesterol (Low density Lipoprotein) were also decreased. It seems atorvastatin is effective to decrease FBS and insulin resistance in diabetic patients.